An expert discusses how to manage a 32-year-old man with both prurigo nodularis and atopic dermatitis who also has asthma, explaining why dupilumab would be the preferred treatment choice over nemolizumab due to safety concerns regarding asthma exacerbation with the latter medication.
An expert discusses how to approach a 58-year-old African American woman with severe prurigo nodularis experiencing extreme itch (9/10 rating) and extensive lesions, emphasizing the need for rapid systemic intervention with nemolizumab due to its faster onset of itch relief compared with other biologics.
Discover how gene expression profiling transforms melanoma and SCC management, enhancing personalized treatment strategies and improving patient outcomes in skin cancer care.
Tildrakizumab, HCP-administered biologics, and lifestyle-based decision-making took center stage in an interactive discussion led by Omar Noor, MD, FAAD, and colleagues.
Topical ruxolitinib, phototherapy, and psychosocial care took center stage in an interactive discussion between Seemal Desai, MD, FAAD, and colleagues, on managing complex vitiligo cases.
At a recent Dermatology Times Case-Based Roundtable event, Stephanie Simmerman, DNP, APRN-C, discussed treatment selection, access challenges, and more for patients with vitiligo.
At a recent Dermatology Times Case-Based Roundtable event, David Cotter, MD, PhD, reviewed treatment considerations for older patients with moderate to severe PsO who are candidates for biologic therapy.
At a recent Dermatology Times Case-Based Roundtable event, Gaurav Singh, MD, MPH, FAAD, FACMS, utilized 3 patient cases to explore the role of GEP testing in melanoma and SCC.
At a recent Dermatology Times Case-Based Roundtable event, Andrew Baker, PA-C, MBA, explored the management of skin cancers with GEP testing through 4 complex cases.
An expert discusses how prurigo nodularis represents one of the most severe itching conditions in dermatology, significantly impacting patients' quality of life and sleep, and explains the importance of breaking the itch-scratch cycle while highlighting recent treatment advances with targeted biologics like dupilumab and nemolizumab.
At a recent Dermatology Times Case-Based Roundtable event, Michael Gold, MD, explored innovative vitiligo treatment strategies through complex cases and emerging therapies.
At a recent Dermatology Times Case-Based Roundtable event, Lisa Swanson, MD, discussed 3 diverse atopic dermatitis patient cases.
The significance of patient education and setting realistic expectations for the often-slow process of repigmentation in vitiligo treatment was a key focus of the discussion.
John Strasswimmer, MD, PhD, spoke on the difficulty of managing adverse effects, the role of interdisciplinary clinical relationships, and the challenges in complex and older patients.
The expert discussion focused on patient management strategies, treatment modalities, and the role of multidisciplinary collaboration.
Serota and other field experts discussed best practices as well as new therapeutics.
At a recent Dermatology Times Case-Based Roundtable event, James Q. Del Rosso, DO, discussed the limitations of topical corticosteroids and the benefits of nonsteroidals.
Nonsteroidal AD therapies are gaining attention due to their rapid effectiveness and ability to offer an alternative to long-term steroid use.
Adelaide A. Hebert, MD, FAAD, stressed the importance of educating patients, setting realistic expectations, and ensuring they adhere to AD treatment plans.
Alexandra Golant, MD, led a Dermatology Times Case-Based Roundtable® event that focused on advancing therapeutic strategies for atopic dermatitis.
New drugs targeting IL-4, IL-13, and IL-31 pathways provide options for tailored eczema treatments.
Lisa Weiss, MMSc, PA-C, and colleagues offered insights on managing severe atopic dermatitis cases with biologics, nonsteroidal treatments, and strategies for addressing physical and emotional impacts.
A recent expert discussion highlighted the importance of long-term planning, including when and how to adjust or transition therapies.
Tina Bhutani-Jacques, MD, highlighted the importance of individualized and informative care while building trust among patients and caregivers.
